Latest Product Pipeline News

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.

Advance ZincTek Limited signals a strong financial turnaround for FY25, expecting a $1.75 million profit before tax driven by increased US sales and strategic operational shifts.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

Osteopore Limited has drawn down an additional A$500,000 from the first tranche of its redeemable convertible notes, bringing total subscriptions close to the A$5 million tranche limit. The funds will support ongoing operations and future growth initiatives.

GreenHy2 Limited has broadened its renewable energy storage portfolio by integrating graphene-based hybrid supercapacitor batteries, reporting robust FY24 growth and advancing key customer trials.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

Nufarm Limited reported a solid half-year performance with a 3% revenue increase and a 40% jump in underlying EBIT, driven by strong crop protection sales and cost improvements. However, net debt rose 12%, reflecting investments in omega-3 production and seed technology expansion.

Nufarm Limited posted a 3% revenue increase to $1.81 billion for the half-year ending March 2025, driven by Crop Protection growth, yet profits fell sharply due to omega-3 inventory write-downs and higher costs. The company withheld its interim dividend amid ongoing operational challenges.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Brightstar Resources has announced significant upgrades to its gold Mineral Resource Estimates at Laverton and Menzies, enhancing confidence in near-term mining operations ahead of its 2025 Definitive Feasibility Study.